ABT data by YCharts The benefits of diversification Abbott Laboratories restarted partial production in the facility that manufactured the infant formula in question only last month. Healthcare giant Abbott Laboratories (NYSE: ABT) has underperformed the market this year. Marketwide worries such as rising inflation and geopolitical tensions aside, the medical devices specialist has been hit hard partly due to issues related to its infant formula business.